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Background: Utility estimates are important health outcomes for economic evaluation of care and treatment
interventions for patients with HIV/AIDS. We conducted a systematic review and meta-analysis of utility measurements
to examine the performance of preference-based instruments, estimate health utility of patients with HIV/AIDS by
disease stages, and investigate changes in their health utility over the course of antiretroviral treatment.
Methods: We searched PubMed/Medline, Cochrane Database of Systematic Review, NHS Economic Evaluation
Database and Web of Science for English-language peer-reviewed papers published during 2000–2013. We selected 49
studies that used 3 direct and 6 indirect preference based instruments to make a total of 218 utility measurements.
Random effect models with robust estimation of standard errors and multivariate fractional polynomial regression were
used to obtain the pooled estimates of utility and model their trends.
Results: Reliability of direct-preference measures tended to be lower than other types of measures. Utility elicited by
two of the indirect preference measures - SF-6D (0.171) and EQ-5D (0.114), and that of Time-Trade off (TTO) (0.151) was
significantly different than utility elicited by Standard Gamble (SG). Compared to asymptomatic HIV patients, symptomatic
and AIDS patients reported a decrement of 0.025 (p = 0.40) and 0.176 (p = 0.001) in utility scores, adjusting for method
of assessment. In longitudinal studies, the pooled health utility of HIV/AIDS patients significantly decreased in the
first 3 months of treatment, and rapidly increased afterwards. Magnitude of change varied depending on the method
of assessment and length of antiretroviral treatment.
Conclusion: The study provides an accumulation of evidence on measurement properties of health utility estimates
that can help inform the selection of instruments for future studies. The pooled estimates of health utilities and their
trends are useful in economic evaluation and policy modelling of HIV/AIDS treatment strategies.
Keywords: Quality of life, Utility, HIV, Longitudinal meta-analysis, Systematic reviewBackground
The rapid scale-up of antiretroviral treatment (ART) ser-
vices globally has brought about substantial progress in
care and treatment for HIV+ patients, transforming HIV/
AIDS from a terminal illness into a chronic illness [1,2].
With ART, patients can be socially and economically pro-
ductive, and thus have not only a longer life, but also a* Correspondence: bach@jhu.edu
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unless otherwise stated.better quality of life. Given this change in the nature of the
disease, monitoring of HIV treatment must consider not
only the prevention of death but also the maximization of
the patients’ quality of life. Traditionally, monitoring HIV
treatment has considered medical outcomes and objective
indicators, such as treatment retention, viral load, CD4
levels and death [3]. However, health-related quality of life
(HRQL) has become a crucial complementary indicator
for monitoring health services and patient-related out-
comes, and evaluating effectiveness of health interventions
in HIV+ populations. Since HIV disease has social andis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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that can capture this complexity.
While in general quality of life is an abstract concept
that is difficult to quantify, health-related quality of life
(HRQL) is a concept that researchers and clinicians have
used to assess a patients’ ability to function in their daily
life and their perceived well-being [4]. Many different
tools have been developed for the measurement of
HRQL, and although they vary widely, it is common that
HRQL is multi-dimensional that captures all the relevant
areas of a patient’s life, including physical health, mental
health and functioning, social interaction and role func-
tioning, and general well-being [5]. HRQL can be assessed
using generic or condition specific measures. Generic
measures are those that are applicable to the general
population and large variety of diseases, while condition-
specific measures are concerned with issues and symp-
toms involved with a specific disease. Generic measures
can typically be categorized as health status profiles, in
which each domain of a patients’ HRQL is scored separ-
ately, or as preference-based HRQL (utility) measures, in
which patients’ individual scores are preference weighted
to achieve an aggregate single score [6]. In health assess-
ment, utility is defined as “a cardinal measure of the pref-
erence for, or desirability of, a specific level of health
status or specific health outcome”. Utility is defined as a
function of health status and the consumption of goods,
services, and leisure over a specified period of time [7].
Utility measures are classified by two major approaches:
the direct and indirect preference. Direct preference-based
measures ask the patients about the value they attach to
their current subjective health states. Meanwhile, indirect
preference-based approaches use preferences from other
samples, usually from general population, to generate pref-
erence index scores for hypothetical health states from a
HRQOL instrument [8].
Various generic and disease-specific HRQL measures
have been applied in HIV populations [5,9-11], most of
which, however, were developed before the advent of
ART. As a result, the breadth of these measures might
include aspects of HRQL which are now less relevant,
while lack increasingly important issues in HIV care and
treatment [11]. For example, HIV patients may have
concerns with sexual functioning, stigma, or body image,
and their HRQL may be negatively affected by some of
the side-effects of antiretroviral medication [5,9]. In
addition, some important methodological considerations
of HRQL measures have emerged, such as their sensitiv-
ity or responsiveness, and the appropriateness of re-
peated use in HIV populations [12]. Since many clinical
interventions for HIV patients result in small, but signifi-
cant changes, it is important that HRQL measures used in
HIV/AIDS populations are sensitive to such treatment
changes [9]. Additionally, since HIV is a progressive andepisodic disease, with different symptoms appearing at dif-
ferent times, any HRQL tool must also be responsive to
patients’ disease states over time. Finally, the ability of a
tool to capture changes in HRQL over time is complicated
by the fact that patients often get acclimated to their own
disease state, and thus rate their current health as higher
although there has not been any change in clinical health
status [3].
One of the most important uses of HRQL assessments
in the sphere of HIV/AIDS is in decision making about the
effectiveness and cost-effectiveness of treatments and inter-
ventions [13]. Generic, preference-based measures provide
a single summary score of HRQL outcomes, an integral
part of the quality-adjusted life-year (QALY) estimation, a
measure which has been widely used in cost-effectiveness
analyses of health interventions [8,14]. Although utility ap-
proaches have been increasingly applied in HIV interven-
tions [15-18], measurements indicate a wide range of
scores and use a wide range of methods [15,16]. There-
fore, pooled estimates of utility measures both aggregate
this data and maximize their external validity, making
them more relevant and useful for policy makers, and
researchers making economic evaluations of HIV inter-
ventions [19].
Previous reviews have compared various instruments in
HIV studies [9,11,12,20], however, they did not sufficiently
identify the applications of preference-based HRQL mea-
sures [9,11,21], nor examine the longitudinal changes in
HRQL over time of these measures [16]. We hypothesized
that the choices of indirect- and direct- preference based
HRQL measures might yield significantly different utility
scores, and that utility of patients deteriorated as the dis-
ease progressed, and could be improved given antiretro-
viral treatment. The objectives of this study were to
systematically review utility measures applied in HIV stud-
ies, estimate health utility of HIV/AIDS patients by disease
stages, and investigate changes in their health utility over
the course of antiretroviral treatment.
Methods
Eligibility criteria
This review followed the PRISMA (Preferred Reporting
Items for Systematic Reviews and Meta-Analyses) guide-
lines when selecting studies for inclusion [22]. Studies
were included if 1) they were written in English in the
period of 2000 up to February 2014 and accessed follow-
ing our search strategy; 2) they were longitudinal or cross-
sectional design studies, employing preference-based
instruments of health utility and reporting the composite
score of health utility, 3) their sample included adult par-
ticipants (≥18 years old) and 4) their full-text articles were
available. To minimize the file-drawer effect, we contacted
principle investigators of studies on health utility and
HIV/AIDS identified but no paper or report published. In
Table 1 Keywords used for search process
General term Health utility term
MeSH MeSH















Antiretroviral therapy Utility scores HUI2
Utility assessment HUI3
Utility measure 15D
Preference based Quality of
well-being
Utility based QWB
Preference elicitation Standard gamble
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utility measures that have been applied to HIV popula-
tions, including indirect utility measures such as: EuroQol
(EQ-5D-3L and EQ-5D-5L), Health utility index (HUI),
Quality of Wellbeing (QWB), Short form-6D (SF-6D),
15D; and direct utility measures such as: Standard Gamble
(SG), Time trade-off (TTO) and Visual Analogue Scale
(VAS). Studies were excluded if they 1) were letters, opin-
ion pieces, editorials, ecological studies, abstracts, and
conference proceedings and full reports were not available;
2) were systematic review or meta-analysis studies; 3) used
non-utility measures and 4) reported health utility from
proxies (e.g. doctors or caregivers). Due to accessibility,
we limited our search strategies only for English-language
papers. Since a previous study by Tengs and Lin did
synthesize utility estimates among HIV/AIDS patients till
2000, we restricted our search for those studies published
after 2000 [16].
Information sources and search strategy
Two separate search strategies were performed, including:
1) searching with a combination of free text keywords and
2) searching for the application of well-known utility mea-
sures in HIV/AIDS field. The search process was con-
ducted from 15th February, 2014 to 8th March, 2014 (date
of last search). Four databases were used for the search
process, including PubMed/Medline, Cochrane Database
of Systematic Review, NHS Economic Evaluation Database
and Web of Science. The search terms used are listed in
Table 1. The search strategy was modified for each data-
base by experienced experts and librarians. Finally, the
bibliographies of selected papers were reviewed and the
authors of unpublished papers were contacted to identify
all of potential relevant studies.
Study selection
After the search was completed, all duplicated studies
were removed. Next, titles and abstracts of all remaining
studies were screened by the research team to ensure
that they matched the selection criteria. All papers
whose title and abstract revealed that it did not match
the selection criteria were excluded. Several further stud-
ies were excluded if their full-text articles revealed that
they did not measure utility or duplicated data.Data items and data collection
Using a data extraction form, three independent reviewers
extracted specified data from the final selected studies.
These reviewers compared their extraction results, dis-
cussing and resolving any disagreements prior to produ-
cing the final data file for the statistical analysis Reliability
of the data extraction among the three independent
reviewers was 90%.Data collected included information about study setting,
study design, sample size, utility measure used, mean or
median utility scores, standard deviations, methods of as-
sessment, length of follow-up, and clinical and demo-
graphic characteristics of respondents. We collected some
additional information about the measures used, including
data about validity, reliability and responsiveness of each
measure (if available).
To define the health utility of each subject based on
clinical characteristics, we divided subjects into 3 disease
stage categories: asymptomatic, symptomatic and AIDS.
However, when we coded disease stage, we found that
HIV/AIDS status was reported in numerous ways. For
example, some of articles simply reported their cohorts
into 3 groups (asymptomatic HIV infection, symptom-
atic HIV infection, and AIDS) [23], while some authors
reported CD4 cell count or the presence of HIV/AIDS-
defining illnesses. In the latter case, we used all available
data to identify the health state based on the current
Centre for Disease Control and Prevention (CDC) guide-
lines [23]. If authors described subjects without indicating
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AIDS status was classified as “combined stages”. If two ar-
ticles described overlapping research findings from the
same dataset, we removed the article that reported less
methodological information.
Data analysis
We used two approaches in analyzing the data. The first
one aimed to obtain the pooled estimates of utility and
examine the influences of study characteristics on these
estimates [24]. We consider every assessment using a
specific tool in both cross-sectional and longitudinal
studies as a single measurement, making a dataset of
218 observations. Since most studies actually applied
several HRQL measures, these studies were considered
as clusters in the model, in which each within-study
measurement was seen as a nested observation [25].
Therefore, we conducted meta-regression analysis, using
a random effect model with robust estimation of stand-
ard error. If the standard deviation of the estimated util-
ity was missing, we calculated it using standard error or
95% confident interval of the estimated utility. In the
first model, comparison of individual measure was con-
ducted. Second, we fit separate models for each of the
subgroups of interest and adjusted for type of HRQL
measure. Finally, we included all study characteristics in
a multivariate model. The second approach was applied
for longitudinal measurements (n = 99) to estimate the
changes in health utility of patients during ART. Trad-
itionally, regression models often provide a linear dose–
response relationship that might not truly reflect the
variability of health outcomes given different time on
ART. To better describe the association between utility
scores and duration on ART, we applied multiple frac-
tional polynomials models which are Intermediate be-
tween polynomials and non-linear curves. We fitted
first-order and second-order fractional polynomial re-
gression with powers (−2,-1, −0.5, 0, 0.5, 1, 2, 3) for the
“duration on ART” to increase the flexibility in estimat-
ing the best-fitting curve to the health utility trajectories.
Data were analyzed using STATA 12.0, ‘xtmixed’ and
‘mfp’ syntax. The details of data analysis and extracted
data set are provided in Additional files 1 and 2.
Ethical approval
All data included in this review were previously pub-
lished and publicly available. We only synthesize and an-
alyzed aggregated data. Therefore, this study did not
require ethical approval.
Results
Our systematic literature search yielded 49 studies for
inclusion in this study (see Figure 1 for flow chart of the
search). We selected these studies for their applicationof nine utility instruments to the field of HIV. These utility
measures included 6 indirect and 3 direct preference-
based measures (see Table 2 for descriptions of the mea-
sures and their psychometric properties). Of the 49 total
studies, 14 utilized longitudinal designs, while 37 studies
were cross-sectional, generating 218 utility estimates.
Of these 218 utility measures, 8 were of asymptomatic
patients, 15 were of symptomatic patients, 56 were from
AIDS patients, and 139 were of a combination of pa-
tients of different stages (Table 3). VAS accounted for
the majority of utility measures (100 times, 45.9%), while
HUI2 was only used in 1 measure (0.5%).
The majority of utility measures were conducted in de-
veloped countries (i.e. USA, UK, Canada, etc.) (with n =
168; 77.1%). 119 utility measures (54.6%) were from
cross-sectional studies and 99 (45.4%) were from longi-
tudinal studies.
Psychometric properties of utility measures in HIV
population
Few studies have reported the reliability of these mea-
sures. Stavem (2005) [17] determined that the test-retest
reliability of EQ-5D, 15D and SF6D was 0.78, 0.90 and
0.94 respectively. Among direct utility measures, Lara
(2008) showed a low reliability of 0.41 for SG while it was
around 0.71-0.83 for TTO and VAS [16]. Many studies
evaluated the validity of utility measures using concurrent
and predictive validation. Several studies established con-
vergent validity of EQ-5D, EQ-VAS, HUI3, SG, TTO and
VAS by demonstrating their correlation with the subscales
of the condition specific MOS-HIV [17,26,27]. In addition,
the EQ-5D and HUI3, along with 3 direct preference-
based measures, were shown to discriminate subjects by
disease severity according to the levels of CD4+ and viral
load. Finally, the EQ-5D single index, 15D and SF-6F dem-
onstrated responsiveness relative to a global rating of
change [18], while the EQ-VAS and HUI3 demonstrated
responsiveness to the development of opportunistic infec-
tions, clinical AIDS-defining events, and adverse events
[18,26,27] (Table 4).
Utility estimates
Data from the 218 utility measurements of 27,951 subjects
were extracted for meta-analysis. The meta-regression re-
sults are shown in Table 5, including Model 7 for compari-
son of individual measure, Model 2-6 for the subgroups of
interest and adjusted for type of HRQL measure and
Model 1 for all characteristics.
Type of instrument used was a significant predictor of
health utility estimates. Adjusting for study characteristics,
the SF-6D and the HUI yielded the highest and lowest
scores, respectively. We found large, statistically significant
differences between utility elicited by SF-6D (0.171), EQ-
5D (0.114), and TTO (0.151) and the reference measure,
Figure 1 Flow of study selection.
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that were not significantly different than SG.
Compared to asymptomatic HIV patients, symptomatic
and AIDS patients reported a decrease in utility score of
0.025 (p = 0.40) and 0.176 (p = 0.001), respectively, when
adjusting for method of assessment, 0.017 (p = 0.65) and
0.173 (p < 0.001), respectively, when adjusting for all study
characteristics.
Health utility of HIV/AIDS patients in developing coun-
tries was 0.082 lower than those who lived in developed
countries. We did not find significant differences in utility
estimates across different years of publication.Longitudinal changes in health utility of HIV/AIDS patients
We used a multivariate fractional polynomial model of the
99 utility measurements from the 14 selected longitudinal
studies to analyse changes in health utility over time (see
Table 5-Model 8, Figures 2 and 3). The model’s coefficients
show that the duration of ART was a significant predictor
of the changes in health utility scores of HIV/AIDS pa-
tients, after adjusting for study characteristics. Health util-
ity of HIV/AIDS patients significantly decreased in the
first 3 months of treatment, and rapidly increased after-
wards (Figure 2). The magnitude of change was also af-
fected by duration of ART, as well as by the methods of













EuroQoL Group mobility, self-care, usual activities,
pain/discomfort and anxiety/depression
5 3 levels 243 −0.59 to 1.00 full health death I, SA* (2 mins)
2. EQ-5D-5L(EuroQol -five
dimensions-5 levels)
EuroQoL Group mobility, self-care, usual activities,
pain/discomfort and anxiety/depression
5 5 levels 3125 −0.45 to 1.00 full health death I, SA* (2 mins)
3. 15D Finland breathing, mental function,
speech (communication),
vision, mobility, usual activities,
vitality, hearing, eating, elimination,
sleeping, distress, discomfort and
symptoms, sexual activity,
and depression
15 5 levels 31 billions 0.00 to 1.00 full health death I, SA* (5–10 mins)
4. Health Utility Index
Mark 2 (HUI2)
Canada sensation, mobility, emotion,
cognition, self-care, pain and fertility
7 3-5 levels 972,000 −0.02 to 1.00 full health death I, SA* (5–10 mins)
5. Health Utility Index
Mark 3 (HUI3)
Canada Vision, hearing, speech,
ambulation, dexterity,
emotion, cognition, and pain
8 5–6 levels 972,000 −0.36 to 1.00 full health death I, SA* (5–10 mins)
6. Short form 6 (SF-6D) UK physical functioning; role limitations;
social functioning; pain; mental
health and vitality
11 4-6 levels 18000 0.00 to 1.00 best health state worst health state I, SA* (2 mins)
7. Standard Gamble (SG) USA - - Continuous - 0.00 to 1.00 full health death I, SA* (2 mins)
8. Time trade-off (TTO) USA - - Continuous - 0.00 to 1.00 full health death I, SA* (2 mins)
9. Visual analog scale (VAS) EuroQoL Group - - Continuous - 0 to 100 full health worst health I, SA* (1 mins)














Table 3 Characteristics of selected utility measurements




Disease stage Asymptomatic 8 3.7%
Symptomatic 15 6.9%
AIDS 56 25.7%
Not reported/Combined* 139 63.8%









Settings Developed countries 168 77.1%
Developing countries 50 22.9%
Study design Cross-sectional 119 54.6%
Longitudinal 99 45.4%
*Data were reported for patients at various disease stage categories.
Tran et al. BMC Health Services Research  (2015) 15:7 Page 7 of 16assessment. Direct preference-based measures resulted in
greater changes in utility scores than indirect preference-
based measures during the first year of treatment. Starting
from the second year, though, the magnitude of change in
health utility measured by indirect-preference instruments
was larger than direct-preference ones. While this trend
was typical for studies conducted in developed countries,
it was slightly different in developing countries. In such
countries as South Africa, Brazil, Thailand, Uganda, and
Vietnam, patients’ health utility markedly increased right
after the initiation of ART, and then changed only slightly
during the first 6 months of treatment, before increasing
rapidly again afterwards (Figure 3).
Discussion
By systematically reviewing studies of health utility
among HIV/AIDS patients, we provide an accumulation
of psychometric evidence of the preference-based HRQL
instruments applied in this patient group. Moreover, we
compared the performance and utility estimates by various
instruments, as well as modelled the changes in health
utility over the course of HIV/AIDS treatment. Prior to
this work, Tengs and Lin did a meta-analysis of health
utility estimates from studies published from 1985–2000
[16]. In this study, we found similar findings that disease
stage is an important predictor of health utility. Also, dif-
ferent HRQL instruments might yield clinically importantdifferences in health utility scores. Moreover, findings of
this study provide most-updated evidence of preference-
based HRQL assessments among patients with HIV/AIDS
during 2000–2013. This is the period when HIV/AIDS
treatment services have been rapidly scaled up in develop-
ing countries. We extend previous work by analyzing the
changes in health utility of patients over the course of
ART. Especially, we revealed that different types of instru-
ments had different levels of responsiveness over the early
and stable periods of ART.
When analyzing the performance of the different in-
struments, we found that the Time Tradeoff (TTO) in-
strument, SF-6D, and EQ-5D yielded higher utility
scores than the reference Standard Gamble (SG) instru-
ment, while the Visual Analogue Scale (VAS), HUI, and
15D showed no statistically significant difference in
measurement than the SG. This is in contrast to various
other studies, in which the use of the SG method gener-
ally yields the highest utility score among direct-
preference instruments [8,72]. Generally, it is believed
that SG yields higher health utilities, because it asks pa-
tients to make a gamble between a chance of good
health and a chance of death, and most people are reluc-
tant to accept a large risk of death to avoid an adverse
health state [72,73]. There has been very little research
about the effect of context on SG and TTO instruments,
and yet our results indicate that these instruments may
perform differently in HIV/AIDS populations [74]. In-
deed, one of the papers included in this review showed
that SG was an unreliable measurement of healthy utility
in HIV/AIDS patients (0.41) and that TTO and VAS
were much more reliable (0.71-0.83) [17]. This low reli-
ability may help explain why SG yielded lower utility
scores, contrary to what was expected.
Given that HIV is a chronic disease that changes over
time, it is essential that HRQL measures are responsive to
clinically significant changes the patient experiences. Most
of the indirect measures included in this study were re-
sponsive to opportunistic infections, clinical AIDS-defining
events, adverse events, or global rating of change, and the
direct preference-based measures were able to discriminate
subjects by disease severity. When analysing the per-
formance of measures throughout the duration of ART,
we found that during the first year of treatment, direct
preference-based measures resulted in greater changes
in utility scores than indirect preference-based mea-
sures, but starting from the second year, this trend re-
versed and indirect preference-based measures resulted
in great changes than direct preference measures. This
may be due to the fact that direct preference-based
measures may reflect the change in subjects’ perception
of their health status rather than a true change in health
status [74,75]. Therefore, change in utility, in short
term, might be influenced by the hope of HIV patients
Table 4 Psychometric properties of selected health utilities measures in HIV population
Tools HIV/AIDS population Reliability Validity Longitudinal validity Floor Ceiling
Subjects Country Sample
size
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*EQ-5D-3L: EuroQol −5 dimensions-3 levels; EQ-5D-5L: EuroQol −5 dimensions-5 levels; HUI2: Health utility index 2; HUI3: health utility index 3; SF-6D: Short form 6-dimensions; SG: standard gamble; TTO: time trade-off;














Table 5 Adjusted effect size by duration of follow-up

































VAS 81 34.6 0.037 (−0.021; 0.095) 0.067
(−0.048; 0.182)







































































Longitudinal 111 47.4 0.033 (−0.027; 0.092)
Disease stages
Asymptomatic 22 9.4
Symptomatic 41 17.5 −0.017 (−0.094; 0.059) −0.025 (−0.084; 0.034)
AIDS 67 28.6 −0.173
(−0.261; −0.086)
−0.176 (−0.278; −0.075)




Non ART 63 26.9

















Table 5 Adjusted effect size by duration of follow-up (Continued)






































Figure 2 Predicted utility score and 95% confidence interval by types of measures based on the best fitting fractional polynomial model.
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may become acclimated to their health status, and thus
become more likely to report a high health status [3].
These results provide some evidence to inform the se-
lection of preference-based HRQL instrument for measur-
ing health utility of HIV/AIDS patients. First, given the
variation of health utility scores based on type of instru-
ment used, and given the difference in direct versus indir-
ect preference measures over time, researchers should
combine both direct and indirect preference-based instru-
ments. This could be done by incorporating VAS intoFigure 3 Predicted utility score and 95% confidence interval by studyother health status profiles. Our review also highlights the
limitations of using generic measures of HRQL in HIV/
AIDS patients. Our meta regression showed steady growth
of health utility scores over the stable period of ART, how-
ever many side-effects of ART, including lipodystrophy,
sleep disturbance, and sexual functioning, have negative
effects on patients’ quality of life and should be reflected
in HRQL measures [12,13,76,77]. Additionally, some
tools, such as EQ-5D-3L, showed a high ceiling effect,
for example, which may affect their responsiveness in
monitoring the outcomes of ART. These findingssettings based on the best fitting fractional polynomial model.
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specific questionnaires that are sensitive to ART. Fi-
nally, we found that these measures performed differ-
ently in developed and developing countries. Patients in
developed countries had higher health utility scores
than patients from the developing world. Additionally,
patients in developed countries demonstrated an initial
decrease in HRQL upon initiation of ART, followed by a
large and steady increase, whereas patients in developed
countries experienced a large initial increase, following
by little change in the first 6 months, and large steady
increase again after that. Since developing countries
have a greater burden of HIV/AIDS, it may be of great
interest for further studies to examine the determinants
of HRQL of patients with HIV/AIDS specifically in
this setting.
Finally, our use of pooled health utility estimates to deter-
mine the changes in HRQL during treatment has significant
implication for economic and clinical evaluation of HIV/
AIDS care and treatment interventions. In particular, the
rapid reduction in health utility during the first 3 months of
ART highlights the importance of intensive support for pa-
tients after ART initiation to relieve both physical and psy-
chological burden experienced by these patients.
The strengths of this meta-analysis include a systematic
approach in synthesizing evidence from the literature. In
addition, we applied multivariate fractional polynomial
models to select the best fitting model for changes in
health utility and length of ART. However, there are some
limitations to be acknowledged. First, aggregated data in
some studies limited the estimate ability of the model. Sec-
ond, the length of ART was inconsistent between different
patient groups and health utility measures. Third, the fre-
quency of application of some instruments, such as 15D
and HUI2, was very small, which resulted in imbalanced
models. Finally, since the selected measures are generic in-
struments, we were not able to identify a set of common
measures, including HIV-specific items, to be used for
comparing across studies.
The pooled estimates of health utilities and trends
throughout the course of ART provided in this study pro-
vide valuable information about the effect of ART on HIV/
AIDS patients health related quality of life, which in turn
can support developing economic models for evaluating
the cost-effectiveness of HIV/AIDS treatment strategies.
Researchers can use estimated utility scores by this study
for quantifying time-dependent health outcomes of inter-
ventions in their cost-effectiveness models. In addition, sig-
nificant reductions in health utility during the first six
month on ART suggest that additional care and support
and intensive monitoring should be incorporated in clinical
practice. Finally this study provides a basis for the selection
of preference-based HRQL instruments for future research
in HIV population.Conclusion
The study provides an accumulation of evidence on
measurement properties of health utility estimates that
can help inform the selection of instruments for future
studies. The pooled estimates of health utilities and their
trends are useful in economic evaluation and policy
modelling of HIV/AIDS treatment strategies.
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